Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Regenerative MedicineCell Therapy

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1594957

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1594957

Stem Cell Therapy

PUBLISHED:
PAGES: 78 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5600
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 16800

Add to Cart

Description

Table of Contents

Global Stem Cell Therapy Market to Reach US$1.1 Billion by 2030

The global market for Stem Cell Therapy estimated at US$379.3 Million in the year 2023, is expected to reach US$1.1 Billion by 2030, growing at a CAGR of 16.4% over the analysis period 2023-2030. Allogeneic Stem Cell Therapy, one of the segments analyzed in the report, is expected to record a 16.7% CAGR and reach US$1.0 Billion by the end of the analysis period. Growth in the Autologous Stem Cell Therapy segment is estimated at 10.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$104.4 Million While China is Forecast to Grow at 15.5% CAGR

The Stem Cell Therapy market in the U.S. is estimated at US$104.4 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$165.6 Million by the year 2030 trailing a CAGR of 15.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 14.3% and 13.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 11.5% CAGR.

Global Stem Cell Therapy Market - Key Trends and Drivers Summarized

How Is Stem Cell Therapy Revolutionizing Patient Care?

Stem cell therapy involves the use of stem cells to regenerate damaged tissues, treat diseases, and restore function in patients. It is used for a wide range of conditions, including hematological disorders, autoimmune diseases, orthopedic injuries, and neurodegenerative diseases. Stem cells, due to their regenerative capabilities, offer the potential for curative treatments that go beyond symptomatic relief, making them an integral part of modern healthcare. The therapy can involve autologous (patient-derived) or allogeneic (donor-derived) stem cells, depending on the condition and the treatment approach. As medical science focuses on regenerative and personalized treatments, stem cell therapy has emerged as a promising solution for both acute and chronic conditions.

What Are the Key Segments in the Stem Cell Therapy Market?

Key types include allogeneic and autologous stem cell therapies, with allogeneic therapies holding a significant market share due to their broader use in treating conditions like hematological malignancies, immune disorders, and inherited diseases. Applications cover orthopedics, neurology, cardiology, hematology, and autoimmune diseases, with hematology representing a major segment driven by the effectiveness of stem cell transplants in treating leukemia, lymphoma, and other blood disorders. End-users include hospitals, research institutes, and specialty clinics, with hospitals leading the market as they provide advanced stem cell therapies for both inpatient and outpatient care.

How Is Stem Cell Therapy Integrated Across Healthcare?

In orthopedics, stem cell therapy is used to treat joint injuries, cartilage damage, and tendon repair by promoting tissue regeneration, reducing pain, and improving mobility. In neurology, stem cells offer potential treatments for conditions like Parkinson’s disease, spinal cord injuries, and stroke recovery by replacing damaged neurons and supporting neural repair. In cardiology, stem cell therapy targets heart tissue regeneration following heart attacks, aiming to improve cardiac function and reduce complications. Additionally, autoimmune diseases like multiple sclerosis and systemic lupus erythematosus are treated with stem cell transplants that reset the immune system and provide long-term remission.

What Factors Are Driving the Growth in the Stem Cell Therapy Market?

The growth in the Stem Cell Therapy market is driven by several factors, including increasing demand for regenerative treatments that address conditions with limited curative options, such as neurodegenerative diseases, heart failure, and immune disorders. Advancements in stem cell research, clinical protocols, and delivery methods have improved the safety, efficacy, and accessibility of these therapies, supporting wider adoption across medical fields. The focus on personalized medicine and tailored treatments has further fueled demand, as stem cell therapy enables individualized care based on patient-specific conditions and genetic profiles. Additionally, growing regulatory approvals, increased clinical trial success rates, and rising investments in biotechnology and regenerative medicine have contributed to market growth, accelerating the development and commercialization of stem cell therapies.

SCOPE OF STUDY:

The report analyzes the Stem Cell Therapy market in terms of US$ by the following Application; Cell Source; Type, and Geographic Regions/Countries:

Segments:

Type (Allogeneic, Autologous); Cell Source (Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs, Other Cell Sources); Application (Musculoskeletal Disorders, Wounds & Injuries, Cardiovascular Diseases, Gastrointestinal Diseases, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 12 Featured) -

  • Advanced Cell Technology
  • Anterogen, Ltd.
  • Biotime, Osiris Therapeutics
  • Cynata
  • Cytori Therapeutics
  • HolostemTerapieAvanzateS.r.l.
  • Human Longevity
  • JCR Pharmaceuticals
  • Medipost
  • Mesoblastand AlloSource
  • NuVasive
  • Osiris Therapeutics, Inc.
  • Pharmicell
  • Promethera Biosciences
  • RTI Surgical
  • Stemcell Technologies
Show more
Product Code: MCP22862

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Stem Cell Therapy - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Chronic Diseases Drives Demand for Stem Cell Therapy
    • Increasing Focus on Regenerative Medicine Spurs Growth in Stem Cell Therapy
    • Advancements in Cell-Based Immunotherapies Propel Market Expansion
    • Rising Adoption in Neurological Disorders Expands Addressable Market
    • Growing Use in Hematological Disorders Strengthens Business Case
    • Expansion of Cardiovascular Applications Spurs Demand for Stem Cell Therapy
    • Emergence of Off-the-Shelf Allogeneic Therapies Enhances Adoption
    • Growing Focus on Rare Disease Treatment Expands Market Potential
    • Rising Approvals for Clinical Trials Accelerates Demand for Stem Cell Therapy
    • Advancements in Gene-Edited Stem Cells Propel Therapeutic Opportunities
    • Rising Focus on Age-Related Degenerative Conditions Fuels Demand
    • Growing Interest in Autologous Therapies Expands Adoption
    • Emergence of Combination Therapies Strengthens Stem Cell Market
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Stem Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Stem Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Stem Cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Allogeneic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Allogeneic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Allogeneic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Autologous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Autologous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Autologous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Gastrointestinal Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Gastrointestinal Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Gastrointestinal Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Musculoskeletal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Musculoskeletal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for Musculoskeletal Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Wounds & Injuries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Wounds & Injuries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 21: World 16-Year Perspective for Wounds & Injuries by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 24: World 16-Year Perspective for Cardiovascular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Adipose Tissue-Derived MSCs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Adipose Tissue-Derived MSCs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 27: World 16-Year Perspective for Adipose Tissue-Derived MSCs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Bone Marrow-Derived MSCs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Bone Marrow-Derived MSCs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 30: World 16-Year Perspective for Bone Marrow-Derived MSCs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 31: World Recent Past, Current & Future Analysis for Other Cell Sources by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 32: World Historic Review for Other Cell Sources by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 33: World 16-Year Perspective for Other Cell Sources by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 34: World Stem Cell Therapy Market Analysis of Annual Sales in US$ for Years 2014 through 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Placental / Umbilical Cord-Derived MSCs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Placental / Umbilical Cord-Derived MSCs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 37: World 16-Year Perspective for Placental / Umbilical Cord-Derived MSCs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Stem Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2014, 2024 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2014, 2024 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2014, 2024 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2014, 2024 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources for the Years 2014, 2024 & 2030
  • JAPAN
    • Stem Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2014, 2024 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2014, 2024 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources for the Years 2014, 2024 & 2030
  • CHINA
    • Stem Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 65: China Recent Past, Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 67: China 16-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2014, 2024 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 70: China 16-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2014, 2024 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 73: China 16-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources for the Years 2014, 2024 & 2030
  • EUROPE
    • Stem Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Stem Cell Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Stem Cell Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Stem Cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2014, 2024 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2014, 2024 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources for the Years 2014, 2024 & 2030
  • FRANCE
    • Stem Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 86: France Recent Past, Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 88: France 16-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2014, 2024 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 91: France 16-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2014, 2024 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 94: France 16-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources for the Years 2014, 2024 & 2030
  • GERMANY
    • Stem Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2014, 2024 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2014, 2024 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2014, 2024 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2014, 2024 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Stem Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 113: UK Recent Past, Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2014, 2024 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2014, 2024 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Rest of Europe Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 124: Rest of Europe 16-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2014, 2024 & 2030
    • TABLE 125: Rest of Europe Recent Past, Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Rest of Europe Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 127: Rest of Europe 16-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2014, 2024 & 2030
    • TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Rest of Europe Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 130: Rest of Europe 16-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Stem Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 131: Asia-Pacific Recent Past, Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Asia-Pacific Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 133: Asia-Pacific 16-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2014, 2024 & 2030
    • TABLE 134: Asia-Pacific Recent Past, Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Asia-Pacific Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 136: Asia-Pacific 16-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2014, 2024 & 2030
    • TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Asia-Pacific Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 139: Asia-Pacific 16-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 140: Rest of World Recent Past, Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of World Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 142: Rest of World 16-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2014, 2024 & 2030
    • TABLE 143: Rest of World Recent Past, Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Rest of World Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 145: Rest of World 16-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2014, 2024 & 2030
    • TABLE 146: Rest of World Recent Past, Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Rest of World Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 148: Rest of World 16-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources for the Years 2014, 2024 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!